HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Feigin, A. Articles by Jankovic, J. Search for Related Content PubMed PubMed Citation Articles by Feigin, A. Articles by Jankovic, J.

A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder

From the University of Rochester Medical Center (Drs. Feigin, Kurlan, McDermott, Dimitsopulos, Trinidad, and Como and Ms. Brower), Rochester, NY; and Baylor College of Medicine (Drs. Chapieski and Jankovic and Ms. Beach), Houston, TX.
Supported by Somerset Pharmaceuticals.
Presented in part at the 47th annual meeting of the American Academy of Neurology, Seattle, WA, May 1995.
Received May 3, 1995. Accepted in final form September 5, 1995.
Address correspondence and reprint requests to Dr. A. Feigin. North Shore University Hospital, 444 Community Drive, Suite 206, Manhasset, NY 11030.

We conducted a double-blind placebo-controlled crossover study to assess the efficacy of deprenyl for attention deficit hyperactivity disorder (ADHD) in children and adolescents with comorbid Tourette's syndrome (TS). Twenty-four subjects (21 boys, 3 girls; mean age 12 years) were enrolled at two sites (University of Rochester and Baylor College of Medicine). The design included two 8-week treatment periods separated by a 6-week washout period. The primary outcome measures for ADHD and tic severity were total scores on the DuPaul Attention Deficit Hyperactivity Scale (DADHS) and the Yale Global Tic Severity Scale (YGTSS). Fifteen subjects completed the study. The primary analysis revealed no statistically significant beneficial effect of deprenyl on the DADHS (mean improvement 1.3; 95% CI, minus 2.7 to 5.3; p equals 0.50). Further post-hoc analyses revealed, however, that the effect of deprenyl in the first period was substantial (p equals 0.02). There was a marginally statistically significant beneficial effect of deprenyl on the YGTSS total score (p equals 0.06). Deprenyl may improve both ADHD and tics in children with TS and warrants further study.

NEUROLOGY 1996;46: 965-968.

This article has been cited by other articles:

				J. Jankovic Tourette's Syndrome N. Engl. J. Med., October 18, 2001; 345(16): 1184 - 1192. [Full Text] [PDF]

				L. Scahill, P. B. Chappell, Y. S. Kim, R. T. Schultz, L. Katsovich, E. Shepherd, A. F.T. Arnsten, D. J. Cohen, and J. F. Leckman A Placebo-Controlled Study of Guanfacine in the Treatment of Children With Tic Disorders and Attention Deficit Hyperactivity Disorder Am J Psychiatry, July 1, 2001; 158(7): 1067 - 1074. [Abstract] [Full Text]

				M. M. Robertson Tourette syndrome, associated conditions and the complexities of treatment Brain, March 1, 2000; 123(3): 425 - 462. [Abstract] [Full Text] [PDF]

				E. J. Garland Reviews : Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats J Psychopharmacol, January 1, 1998; 12(4): 385 - 395. [Abstract] [PDF]